BeiGene, Ltd. (BEIGF) Stock Price, News, Quote & History - Yahoo Finance
Advertisement
U.S. markets open in 9 hours 18 minutes
Advertisement

BeiGene, Ltd. (BEIGF)

Other OTC - Other OTC Delayed Price. Currency in USD
14.290.00 (0.00%)
At close: 11:59AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close14.29
Open14.29
BidN/A x N/A
AskN/A x N/A
Day's Range14.29 - 14.29
52 Week Range12.57 - 16.78
Volume2,100
Avg. Volume0
Market Cap17.727B
Beta (5Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BEIGF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BEIGENE LTD
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • CNW Group

    Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

    BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for the use of BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) who have received at least two prior systemic therapies.

  • Insider Monkey

    10 Blue-Chip Stocks At 52-Week Lows

    In this piece, we will take a look at the ten blue chip stocks at 52 week lows. If you want to skip the latest stock market news, then you can take a look at the 5 Blue-Chip Stocks At 52-Week Lows. The end of January has provided the media and investors with crucial information […]

  • CNW Group

    Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)

    BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and Quebec have publicly listed BRUKINSA® (zanubrutinib), a second generation inhibitor of Bruton's tyrosine kinase (BTK), for the treatment of adults living with chronic lymphocytic leukemia (CLL), the most common form of leukemia in adults. The Régie de l'assurance maladie du Québec listing came into effect December 13, 2023, and the Ontario Drug Benef